Investigation of Complaint for Specific Swallowing Drugs in Parkinson Disease Patients
Introduction: Parkinson disease is a universal and neurodegenerative pathology that affects the basal ganglia, resulting in progressive death of cells producing the neurotransmitter dopamine present in the substantia nigra area of the brain, responsible for motor control part of the human body. The drug intervention in Parkinson is the main form of treatment for the disease and control signs and symptoms.
Objective: The study aimed to investigate whether there are specific complaints in swallowing drugs in patients with a diagnosis of Parkinson disease.
Methods: An observational, cross-sectional study involving 50 patients interviewed through a questionnaire directed to specific issues in patients attended at the outpatient clinic of movement disorders, in a neurological service from a university hospital, aiming to search the complaint of swallowing commercially available types of medicines, which are tablets, caplets, pills, and syrup, and the usual management adopted by this population.
Results: The study subjects had a mean age of 64.3 years (±11.7), with a prevalence of males (64%). From the 50 patients interviewed, 21 (42%) complained of swallowing. The tablet (76.2%) was the drug submission that causes more difficulty to swallow, with the breaking of the tablet (43.7%) a maneuver most used by the population.
Conclusion: The specific complaint for swallowing medicines by parkinsonian patients was present in almost half of the investigated population, most prevalent for the drug form called tablet.